Health Canada approves Moderna’s combined COVID, flu shot for some - National
Health Canada approved Moderna's mFLUSIVA (mRNA flu vaccine) and mCOFLU (combined flu and COVID-19 vaccine) for adults 50+. According to the company, Canada is the first country to approve both. Moderna plans to work with health authorities for future availability, but the shots won't be part of the 2026-2027 season.
How this was made
The 30-second read
Why it matters
This is a regulatory milestone that expands Moderna’s eligible Canadian market for mRNA respiratory vaccination, but the lack of a stated rollout date and exclusion from the next immunization season reduces immediate revenue visibility.
Market read
Traders may reassess Moderna’s international commercialization trajectory and pipeline execution, though near-term financial impact is uncertain due to rollout timing.
What to watch
Canada’s uptake depends on provincial procurement, pricing, and immunization partner adoption; without those details, the market may discount the approval’s financial significance.
Background
Health Canada authorized Moderna’s mFLUSIVA (mRNA flu) and mCOFLU (combined influenza and COVID-19) for adults 50+; the company notes the US and Europe approvals occurred earlier.
Ticker impact
Health Canada approved Moderna’s mRNA flu vaccine (mFLUSIVA) and its combined COVID-19 and flu shot (mCOFLU) for adults 50+.
Likely positive bias as the market prices in broader ex-Canada commercialization and improved product pipeline credibility.
The article is a first-time Canada approval for both products, which is a concrete commercialization milestone, though it provides no sales timing or revenue figures.
Market effects
Supports the mRNA vaccine platform narrative and may lift sentiment toward other respiratory vaccine developers, but the impact is company-specific.
Canada authorization can shift near-term procurement and tender expectations for public immunization programs in Canada.
Adds to a growing set of international approvals, reinforcing cross-market commercialization momentum for Moderna’s mRNA respiratory portfolio.
Counterpoint
The article says the shots will not be part of the 2026-2027 immunization season and does not specify when availability begins, limiting near-term earnings impact.
Key entities
- companyModerna
Company receiving Health Canada authorization for mFLUSIVA and mCOFLU for adults 50+.
- regulatorHealth Canada
Canada’s top health agency that approved the two Moderna vaccines.
- productmFLUSIVA
Moderna’s mRNA influenza vaccine authorized for adults 50+ in Canada.
- productmCOFLU
Moderna’s combined influenza and COVID-19 vaccine authorized for adults 50+ in Canada.
